Registry-listed formulations

Olopatadine hydrochloride · chembl:CHEMBL1719

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

31 source entries across 28 studies. This list may not include all unresolved or historical entries.

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine Hydrochloride Nasal Spray 0.6%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine HCL Nasal Spray, 0.6%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine hydrochloride 0.6% nasal spray (PATANASE)Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine Hydrochloride Nasal Spray 0.6%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine HCl Nasal Spray, 0.6%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine HCL (Patanase) Nasal Spray, 0.6%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine Hydrochloride Ophthalmic Solution, 0.1%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine hydrochloride ophthalmic solution 0.1%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine hydrochloride 0.1% ophthalmic solutionRegistry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)Registry intervention
Linked study entry; product equivalence not established
View study and source
olopatadine hydrochloride 0.1% ophthalmic solutionRegistry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine hydrochloride ophthalmic solution, 0.7%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine Hydrochloride 0.1% Ophthalmic SolutionRegistry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine hydrochloride 0.2%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine hydrochloride ophthalmic solution, 0.2%Registry intervention
Linked study entry; product equivalence not established
View study and source
Olopatadine HydrochlorideRegistry intervention
Linked study entry; product equivalence not established
View study and source

Success Metrics

Clinical Success Rate

100.0%

Based on 26 completed trials

Completion Rate

100%(26/26)

Active Trials

0(0%)

Results Posted

54%(14 trials)

Phase Distribution

Phase 3

36%

Phase 1

Not Applicable

Phase 2

11%

Phase 4

46%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution28 total trials

Phase 1Safety & dosage

1(3.6%)

Phase 2Efficacy & side effects

3(10.7%)

Phase 3Large-scale testing

10(35.7%)

Phase 4Post-market surveillance

13(46.4%)

N/ANon-phased studies

1(3.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

96.3%

26 of 27 finished

Non-Completion Rate

3.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(26)

Terminated(1)

Other(1)

Detailed Status

Completed26

unknown1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (3.6%)

Phase 23 (10.7%)

Phase 310 (35.7%)

Phase 413 (46.4%)

N/A1 (3.6%)

Trials by Status

unknown14%

completed2693%

withdrawn14%

Recent Activity

0 active trials

Showing 5 of 28

unknownphase_4

Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis

NCT03186755

completedphase_4

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

NCT05265910

completedphase_4

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

NCT04708821

withdrawnphase_3

Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis

NCT01657240

completedphase_2

Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT03444506

View all 28 trials

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more

NCT03186755Phase 4

Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis

Unknown

NCT05265910Phase 4

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

Completed

NCT04708821Phase 4

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

Completed

NCT01657240Phase 3

Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis

Withdrawn

NCT03444506Phase 2

Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)

Completed

NCT00789555Phase 4

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

Completed

NCT02322216Phase 3

Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects

Completed

NCT00331500Phase 3

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Completed

NCT02251613Phase 4

Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan

Completed

NCT01109485Phase 4

Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients

Completed

NCT01326858Phase 1

Safety and Comfort of AL-4943A Ophthalmic Solution

Completed

NCT01363700Phase 3

Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Completed

NCT01697969Phase 4

Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients

Completed

NCT01743027Phase 3

Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

Completed

NCT01037179Phase 3

An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

Completed

NCT00987272Phase 3

Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects

Completed

NCT01119287Phase 4

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

Completed

NCT01450176Not Applicable

Comparing Patient Satisfaction With Pataday or Bepreve

Completed

NCT01479374Phase 3

Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model

Completed

NCT01272089Phase 4

A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis